Scynexis Lands $200M+ BARDA Deal for Antifungal SCY-247
A federal biodefense contract worth more than $200 million puts Scynexis' second-generation antifungal SCY-247 on government money, with the shares up 2.96% on the day.
Scynexis (NASDAQ: SCYX) said it has secured a BARDA contract worth more than $200 million to develop SCY-247, an investigational treatment for serious drug-resistant fungal infections; the shares traded at $4.52, up 2.96%, as of 16:35 GMT on 28 September 2026.
Scynexis Inc. (NASDAQ: SCYX) has secured a contract worth more than $200 million from the Biomedical Advanced Research and Development Authority to develop SCY-247, an investigational medicine aimed at serious drug-resistant fungal infections. The award pushed the shares to $4.52, up 2.96% on the day, as of 16:35 GMT on 28 September 2026, after an intraday run as high as $5.15.
BARDA sits inside the US Department of Health and Human Services and funds countermeasures against threats the commercial market will not pay to solve on its own — pandemic influenza, chemical and radiological agents, and, increasingly, antimicrobial resistance. Its contracts are typically staged: a base period of committed money followed by option periods that the agency can exercise, or decline to exercise, as data arrive.
Why an antifungal gets federal money
Drug-resistant fungal infections are a textbook case of market failure. The patient populations are small relative to antibacterial markets, the sickest patients are in hospital intensive care, and courses of therapy are short — a combination that makes it hard for a developer to earn back the cost of a phase 3 programme. That is precisely the gap BARDA-style funding is designed to plug, by paying for development rather than waiting for a commercial return to justify it.
For Scynexis, the strategic logic is continuity. SCY-247 is an investigational follow-on in the company's antifungal franchise, and a government partner that pays development costs changes the arithmetic of running a late-stage programme at a small-cap company. Non-dilutive funding — cash that does not require issuing new shares — is the scarcest resource in small-cap biotech, and a contract of this scale is unusual for a company of Scynexis' size.
What the award does to the cash question
The perennial question for a clinical-stage developer is runway: how many quarters of spending the balance sheet covers before the next financing. A contract that reimburses development work for a lead asset does two things at once. It shifts programme spend off the company's own income statement, and it removes the immediate pressure to raise equity at a share price that sits in the low single digits.
It is worth being precise about what a headline contract value is and is not. More than $200 million is the ceiling if every option is exercised and every milestone met; it is not cash in the bank today. Investors should watch the split between the committed base period and the optional extensions, the timing of reimbursements, and whether the government retains rights over pricing or supply. Those terms determine how much of the $200 million figure ever reaches the company.
The award was reported by Endpoints News, alongside a set of other sector items on the same day.
Bristol Myers puts early numbers on a dual-targeting CAR-T
Separately, Bristol Myers Squibb (NYSE: BMY) released early data for a dual-targeting CAR-T therapy. CAR-T treatments re-engineer a patient's own T cells to recognise a marker on cancer cells; the persistent weakness of the approach is antigen escape, where the tumour stops expressing the single target and the therapy loses its grip. Aiming at two antigens at once is the industry's main structural answer to that problem, and early readouts are watched for whether the second target buys durability without adding toxicity.
Separately, Bristol Myers Squibb (NYSE: BMY) released early data for a dual-targeting CAR-T therapy.
Bristol Myers shares traded at $63.55, up 1.10%, as of 16:35 GMT on 28 September 2026, within a day range of $62.30 to $63.59 — a move consistent with an early-stage dataset at a company of its size rather than a pipeline-defining event. Both stocks were firmer against a softer tape: the S&P 500 tracker (SPY) was at $767.89, down 0.45%, the Nasdaq 100 tracker (QQQ) at $738.85, down 0.76%, and the Dow tracker (DIA) at $515.45, down 0.39%.
MediciNova takes the day's heaviest hit
The sharpest move among the companies in the day's biotech news flow belonged to MediciNova Inc. (NASDAQ: MNOV), which traded at $1.72, down 33.33% from a prior close of $2.58, with a day range of $1.69 to $2.45. A one-third single-session decline in a clinical-stage name is the market's standard response to a disappointing readout, a regulatory setback or a financing on punishing terms; the price action alone does not identify which.
The broader day also carried items involving Tolerance Bio, Tanabe, Lepu Medical and Synphatec — a reminder that the sector's news cycle runs on a mix of government contracting, early clinical data and cross-border deal activity rather than on any single narrative.
What to watch from here
- Contract structure. How much of the Scynexis award is base funding versus optional, and over how many years it is spread.
- Clinical milestones for SCY-247. BARDA money typically unlocks on defined development steps; those dates become the stock's calendar.
- Equity issuance. Whether Scynexis still comes to market for capital despite the award is the cleanest signal of how much near-term cash the contract actually delivers.
- Bristol Myers' next CAR-T cut. Early data sets the question; the follow-up on durability and safety answers it.
- MediciNova's disclosure. The reason behind a 33.33% drop matters more than the drop itself for anyone assessing the name.
The wider antimicrobial-resistance trade
Antifungal resistance has moved up the public-health agenda as hospital-acquired infections with limited treatment options spread, and governments have responded with pull and push incentives rather than leaving the field to commercial economics. A contract of this size signals that a specific asset has cleared an agency's internal bar for strategic importance — a form of technical validation that private capital tends to price in.
For shareholders, the practical effect is that a portion of Scynexis' development risk is now underwritten by a counterparty that does not demand equity in return. That does not make the science work. It does mean the company can find out whether it works without handing over another slice of the business first.
Key facts
- SCYX price: $4.52, +2.96%, as of 16:35 GMT 28 Sep 2026
- Contract value: More than $200 million from BARDA
- Asset funded: SCY-247, investigational drug-resistant fungal infection treatment
- Biggest sector mover: MNOV at $1.72, -33.33% on the day
Frequently asked questions
What is BARDA and why does it fund drugs?
BARDA is the Biomedical Advanced Research and Development Authority, part of the US Department of Health and Human Services. It funds medical countermeasures against public-health threats that commercial markets underinvest in, including pandemic pathogens, chemical and radiological agents, and antimicrobial resistance. Its contracts usually combine committed base funding with optional periods the agency can exercise as development milestones are met.
What is SCY-247?
SCY-247 is Scynexis' investigational treatment for serious drug-resistant fungal infections. It has not been approved, and the BARDA contract funds its continued development rather than marking any regulatory clearance. The award is worth more than $200 million across its full potential value, subject to the contract's milestone and option structure.
Does the $200 million go to Scynexis immediately?
No. A headline contract value of more than $200 million represents the maximum payable if every option period is exercised and every milestone achieved. The committed base funding is typically a fraction of that, with the remainder contingent on development progress and the agency's decisions over the life of the contract.
How did Scynexis shares react?
Scynexis traded at $4.52, up 2.96% from a prior close of $4.39, as of 16:35 GMT on 28 September 2026. The stock reached $5.15 intraday before easing, with a session low of $4.45. The gain came against a weaker broad market, with the S&P 500 tracker down 0.45% on the day.
What is a dual-targeting CAR-T therapy?
CAR-T therapy re-engineers a patient's T cells to attack a specific marker on cancer cells. Single-target versions can fail when tumours stop expressing that marker, a problem called antigen escape. Dual-targeting designs aim at two markers simultaneously to reduce that escape route. Bristol Myers Squibb released early data for such a therapy, with its shares at $63.55, up 1.10%.
Why did MediciNova fall so sharply?
MediciNova traded at $1.72, down 33.33% from a prior close of $2.58, with a day range of $1.69 to $2.45. The specific trigger was not detailed in the available information. Declines of that magnitude in clinical-stage biotechs typically follow disappointing trial data, a regulatory setback or a dilutive financing, but the price move alone does not confirm the cause.
